Short answer
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). ADMA announced financial results for the three months ended September 30, 2026.
ADMA BIOLOGICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- ADMA announced financial results for the three months ended September 30, 2026
- Business update accompanies the quarterly results
- Exhibit 99.1 contains the detailed financial figures and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $141.1M, up 5% YoY, while ASCENIV revenue rose 31% to $124.7M
- GAAP net income $49.9M, up 37%, with basic EPS $0.22, up 47%
- Gross margin expanded to 71% from 56%, driven by ASCENIV mix and yield-enhanced manufacturing
- BIVIGAM revenue fell to $15.4M from $23.8M, highlighting competitive pricing and channel inventory pressure
- FY2026 guidance maintained at least $530M revenue, while adjusted net income rose to at least $180M and adjusted EBITDA to $275M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADMA BIOLOGICS, INC. 8-K filings
Get the next ADMA 8-K as it lands
Follow ADMA for push alerts, or ask the research agent what this filing means.